Abstract
Objectives
Bisphosphonate-associated osteonecrosis of the jaws is a serious side effect that mainly occurs in patients receiving highly potent, nitrogen-containing bisphosphonates. Usually the diagnosis is made due to exposed bone and a nonhealing wound. Neutrophil granulocytes are essential for sufficient wound healing; therefore, the influence of different bisphosphonates on neutrophil granulocytes was the focus of this study.
Material and methods
The effect of nitrogen-containing bisphosphonates (ibandronate, pamidronate, and zoledronate) and one non-nitrogen-containing bisphosphonate (clodronate) on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes in human whole blood was analyzed using standard cytometric flow assays.
Results
Chemotaxis of neutrophils was reduced by almost 50 % when cells were treated with ibandronate and zoledronate. All tested nitrogen-containing bisphosphonates moderately increased the percentage of phagocytizing neutrophils, whereas the percentage of oxidizing cells was extremely affected. Zoledronate increased the oxidative burst activity even at low concentrations. Treatment with ibandronate and pamidronate reached the same level, but only in at least 10 times the higher concentrations. The maximal burst activity of a single cell reached nearly 150 % compared to control. In this case, zoledronate also caused maximal effects even at low concentrations. Clodronate did not show any effects.
Conclusion
The results show a proinflammatory effect of the nitrogen-containing effect on neutrophil granulocytes which might contribute to the development of osteonecrosis.
Clinical relevance
The altered neutrophil defense might play a key role in the pathogenesis of bisphosphonate-associated osteonecrosis of the jaws, although the underlying causation between inflammatory reaction and the development of necrosis is yet unknown.
Similar content being viewed by others
References
Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, Norimatsu H (2005) The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 23(Suppl):36–42
Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14(1):35–41. doi:10.1007/s00784-009-0266-4
Ziebart T, Pabst A, Klein MO, Kammerer P, Gauss L, Brullmann D, Al-Nawas B, Walter C (2009) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15(1):105–111. doi:10.1007/s00784-009-0365-2
Pabst AM, Ziebart T, Ackermann M, Konerding MA, Walter C (2013) Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay. Clin Oral Investig. doi:10.1007/s00784-013-1060-x
Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B (2011) Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis 17(2):194–199. doi:10.1111/j.1601-0825.2010.01720.x
Pabst AM, Ziebart T, Koch FP, Taylor KY, Al-Nawas B, Walter C (2011) The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes—in vitro study. Clin Oral Investig 16(1):87–93. doi:10.1007/s00784-010-0507-6
Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2009) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14(1):35–41. doi:10.1007/s00784-009-0266-4
Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R (2009) Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 67(1):159–161. doi:10.1016/j.joms.2008.09.015
Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, Santamaria C, Rosinol L, de la Rubia J, Hernandez MT, Garcia-Navarro I, Lahuerta JJ, Gonzalez M, San Miguel JF (2008) Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112(7):2709–2712. doi:10.1182/blood-2008-04-147884
Tarassoff P, Csermak K (2003) Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61(10):1238–1239
Walter C, Grotz KA, Kunkel M, Al-Nawas B (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15(2):197–202. doi:10.1007/s00520-006-0120-z
Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54(5):1066–1072. doi:10.1016/j.eururo.2008.06.070
Walter C, Laux C, Sagheb K (2013) Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study. Clin Oral Investig. doi:10.1007/s00784-013-0974-7
Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, Kirkpatrick CJ (2007) Actinomycosis of the jaws—histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451(6):1009–1017. doi:10.1007/s00428-007-0516-2
Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, Rizzoli R, Saffar JL, Samson J (2009) Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone 45(5):843–852. doi:10.1016/j.bone.2009.07.011
Broughton G 2nd, Janis JE, Attinger CE (2006) Wound healing: an overview. Plast Reconstr Surg 117(7 Suppl):1e-S–32e-S. doi:10.1097/01.prs.0000222562.60260
Lamster IB (2000) Grbic JT (1995) Diagnosis of periodontal disease based on analysis of the host response. Periodontol 7:83–99
Bosshardt DD, Lang NP (2005) The junctional epithelium: from health to disease. J Dent Res 84(1):9–20
Lorenzo J, Horowitz M, Choi Y (2008) Osteoimmunology: interactions of the bone and immune system. Endocr Rev 29(4):403–440. doi:10.1210/er.2007-0038
Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, Bauss F, Ehrenfeld M, Schieker M (2010) Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 68(11):2837–2845. doi:10.1016/j.joms.2010.07.017
Montazeri AH, Erskine JG, McQuaker IG (2007) Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 79(1):69–71. doi:10.1111/j.1600-0609.2007.00872.x
Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT (2002) Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62(9):2708–2714
Walker K, Olson MF (2005) Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 15(1):62–68. doi:10.1016/j.gde.2004.11.001
Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW (2003) Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170(1):246–252. doi:10.1097/01.ju.0000070685.34760.5f
Wu L, Zhu L, Shi WH, Zhang J, Ma D, Yu B (2009) Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol 602(1):124–131. doi:10.1016/j.ejphar.2008.10.043
Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S, Russell RG (1996) Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 11(10):1482–1491. doi:10.1002/jbmr.5650111015
Kuiper JW, Forster C, Sun C, Peel S, Glogauer M (2012) Zoledronate and pamidronate depress neutrophil functions and survival in mice. Br J Pharmacol 165(2):532–539. doi:10.1111/j.1476-5381.2011.01592.x
Coughlan AM, Freeley SJ, Robson MG (2012) Humanised mice have functional human neutrophils. J Immunol Methods 385(1-2):96–104. doi:10.1016/j.jim.2012.08.005
Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, Okkenhaug K, Vanhaesebroeck B, Turner M, Webb L, Wymann MP, Hirsch E, Ruckle T, Camps M, Rommel C, Jackson SP, Chilvers ER, Stephens LR, Hawkins PT (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106(4):1432–1440. doi:10.1182/blood-2005-03-0944
Favot CL, Forster C, Glogauer M (2013) The effect of bisphosphonate therapy on neutrophil function: a potential biomarker. International journal of oral and maxillofacial surgery 42(5):619–626. doi:10.1016/j.ijom.2012.12.011
Yao S, Huang D, Chen CY, Halliday L, Zeng G, Wang RC, Chen ZW (2010) Differentiation, distribution and gammadelta T cell-driven regulation of IL-22-producing T cells in tuberculosis. PLoS Pathog 6(2):e1000789. doi:10.1371/journal.ppat.1000789
Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2):384–392
Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G (2003) Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197(2):163–168
Thompson K, Rojas-Navea J, Rogers MJ (2006) Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway. Blood 107(2):651–654. doi:10.1182/blood-2005-03-1025
Thompson K, Rogers MJ (2004) Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 19(2):278–288. doi:10.1359/JBMR.0301230
Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139(1):101–111. doi:10.1111/j.1365-2249.2005.02665.x
Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K (2009) Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144(2):245–250. doi:10.1111/j.1365-2141.2008.07435.x
Kabelitz D (2008) Small molecules for the activation of human gammadelta T cell responses against infection. Recent Pat Antiinfect Drug Discov 3(1):1–9
Garcia VE, Sieling PA, Gong J, Barnes PF, Uyemura K, Tanaka Y, Bloom BR, Morita CT, Modlin RL (1997) Single-cell cytokine analysis of gamma delta T cell responses to nonpeptide mycobacterial antigens. J Immunol 159(3):1328–1335
Cipriani B, Borsellino G, Poccia F, Placido R, Tramonti D, Bach S, Battistini L, Brosnan CF (2000) Activation of C-C beta-chemokines in human peripheral blood gammadelta T cells by isopentenyl pyrophosphate and regulation by cytokines. Blood 95(1):39–47
Poccia F, Agrati C, Martini F, Mejia G, Wallace M, Malkovsky M (2005) Vgamma9Vdelta2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy. Immunol Lett 100(1):14–20. doi:10.1016/j.imlet.2005.06.025
Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61(5):386–392
Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G (2003) Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 23(11):649–654. doi:10.1089/107999003322558782
Jan MS, Huang YH, Shieh B, Teng RH, Yan YP, Lee YT, Liao KK, Li C (2006) CC chemokines induce neutrophils to chemotaxis, degranulation, and alpha-defensin release. J Acquir Immune Defic Syndr 41(1):6–16
Agrati C, Cimini E, Sacchi A, Bordoni V, Gioia C, Casetti R, Turchi F, Tripodi M, Martini F (2009) Activated V gamma 9V delta 2 T cells trigger granulocyte functions via MCP-2 release. J Immunol 182(1):522–529
Rossini M, Adami S, Viapiana O, Fracassi E, Ortolani R, Vella A, Zanotti R, Tripi G, Idolazzi L, Gatti D (2012) Long-term effects of amino-bisphosphonates on circulating gammadelta T cells. Calcif Tissue Int 91(6):395–399. doi:10.1007/s00223-012-9647-9
Thurnher M, Nussbaumer O, Gruenbacher G (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 18(13):3524–3531. doi:10.1158/1078-0432.CCR-12-0489
Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9(32):2643–2658
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hagelauer, N., Pabst, A.M., Ziebart, T. et al. In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes. Clin Oral Invest 19, 139–148 (2015). https://doi.org/10.1007/s00784-014-1219-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00784-014-1219-0